CN106727301A - A kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm and preparation method thereof - Google Patents
A kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm and preparation method thereof Download PDFInfo
- Publication number
- CN106727301A CN106727301A CN201611242931.8A CN201611242931A CN106727301A CN 106727301 A CN106727301 A CN 106727301A CN 201611242931 A CN201611242931 A CN 201611242931A CN 106727301 A CN106727301 A CN 106727301A
- Authority
- CN
- China
- Prior art keywords
- ambroxol
- sustained release
- mixed suspension
- suspension preparation
- release mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm and preparation method thereof, it is characterized in that the sustained release mixed suspension preparation is made up of ambroxol coated granule and suspending system, the pastille particulate film coating gained that the ambroxol coated granule by ambroxol hydrochloride and resin formed after ion exchange, the suspending system is made up of suspending agent, flavouring, PH conditioning agents, preservative, pigment and purified water, and preparation method is comprised the following steps：The resin carrier and film coating of ambroxol are first prepared, then ambroxol coated granule addition suspending system is prepared into pastille suspension；The present invention is compared with other formulations, and convenient drug administration, bioavilability is high, and curative effect stabilization is lasting, and toxic and side effect is small, it is easy to the medication of children, old man and dysphagia patients.
Description
Technical field
The present invention relates to pharmaceutical technology field, more particularly to a kind of breathing problem eliminating the phlegm sustained release mixed suspension preparation and its system
Preparation Method.
Background technology
China's air pollution in recent years is serious, causes the incidence of disease of diseases of respiratory system and case fatality rate to remain high, at present,
It has been the dead the third-largest factor of China human mortality.Therefore, the exploitation for the treatment of medicament for treating respiratory system thing also turns into drug research
One pith.In the case of respiratory tract infection (such as chronic bronchitis breathing problem), often produce a large amount of
Sputum, the presence of phlegm blocks respiratory tract, easily causes cough, pants, or even causes to have difficulty in breathing, especially children and old man
Often there is spitting difficult so the application of expectorant is very necessary.Ambroxol hydrochloride series is clinically to act on most strong at present
Expectorant, its curative effect is extremely affirmed both at home and abroad, market sale increase it is steady in have into.
Ambroxol hydrochloride is the respiratory mucus conditioning agent of a new generation, with very strong phlegm-dispelling functions, and to alveolar surface
The synthesis and secretion of active material have significant facilitation.Suitable for acute and chronic breathing problem (such as acute and chronic branch gas
Guan Yan, bronchial astehma, bronchiectasis, pulmonary tuberculosis etc.) thick sputum, the dys-expectoration that cause.
Ambroxol hydrochloride belongs to mucolytic agent, can stimulate bronchial mucous gland, increases the secretion of neutral mucopolysacchauide, reduces
The synthesis of acid mucopolysaccharide simultaneously promotes it to be metabolized, so that the reason of respiratory mucus stops property tends to normal, is conducive to sputum to arrange
Go out.Zoopery and clinical test confirm that the viscosity of sputum can reduce by more than 50% after medication.Ambroxol hydrochloride activation mucus is fine
Hair function, is conducive to the discharge of airway secretions, experiment to show that ciliary beat frequency increased 10.8% after medication.
Compared with the first generation and second generation expelling phlegm drugses, ambroxol hydrochloride in addition to being acted on powerful mucolysis, its
Maximum feature is that it can stimulate II types alveolar epithelial cells and clara cell, increases the synthesis of alveolar surfactant and divides
Secrete, so as to effectively strengthen mucus transport, promote expectoration.Also there is ambroxol hydrochloride many protections to make to respiratory system
With：
1st, the free dioxygenase gene of antioxidation reactivity is in many PUD Ds such as idiopathic fibrosis, adult's breathing
Distress syndrome, all plays an important role in the morbidity of cystic fibrosis.Strengthening antioxidant defense mechanisms in these diseases can
It can be a kind of feasible therapy approach.Ambroxol can remove oxide OH-, HOCl, weaken BHR, stimulate thin
The secretion of cellular surface active material.
2nd, the release ambroxol of inflammatory mediator is reduced to people's body of gland mast cell (1000nnol/L) and skin that activate respectively
The inhibiting rate of skin mast cell (100mmol/L) histamine releasing can reach more than 50%.It is different from N-acetylcystein, ammonia
Bromine rope can not only suppress the release of leucocyte and mast cell acute mediators, can also reduce basophilic granulocyte release immune
Instrumentality-cell factor.Can be applied to the treatment of abnormalism respiratory disease.
3rd, the Effect study to airway smooth muscle shows that ambroxol has cough inhibitory action, and histamine is induced
The usual flesh contraction of air flue becomes apparent from.Mechanical irritation induces cat cough reflex, and intraperitoneal application ambroxol suppresses cough anti-
The effective percentage penetrated reaches 51.6%, and oral availability is 37.04%.When ambroxol concentration reaches 10-4mol/L, the lung of cavy
Smooth muscle is completely loose.
Additionally, ambroxol hydrochloride can also increase drug concentration of the antibiotic in air flue, antibiotic is assisted to penetrate into bronchus
In secretion, strengthen the sterilizing ability of antibiotic.Ambroxol hydrochloride clinic apply for many years, phlegm-dispelling functions by force, and with compared with
Good tolerance and security.
In recent years, the study hotspot of ambroxol hydrochloride is turned to for chest, abdominal postoperative prevention pulmonary infection, atelectasis.
The particularly preoperative patient with branch or other basic PUD Ds slowly, Post operation is reduced due to body fluid, and stomach tube retains, and is crouched
The reasons such as bed, wound pain, cause thick sputum to be difficult expectoration, and serious causes pulmonary infection even threat to life.
The content of the invention
It is an object of the present invention to provide a kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm and preparation method thereof.Will
The technical problem of solution is the shortcoming and defect for overcoming prior art, convenient drug administration, bioavilability are high, curative effect stabilization is lasting,
Toxic and side effect is small, can solve the problem that the problem of children, the validity of old man and dysphagia patients medication, security and compliance.
To solve above technical problem, the technical scheme is that：
A kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm, containing ambroxol coated granule and suspending system, by weight
Percentage said preparation contains following composition：Ambroxol coated granule is 0.5%~10%, and suspending system is 90%~99.5%.
In ambroxol coated granule of the invention, contain ambroxol, ion exchange resin, coating material and plasticizer.
In suspending system of the invention, contain suspending agent, flavouring, PH conditioning agents, preservative, pigment and purified water.
In ambroxol coated granule of the invention, described ion exchange resin from styrene cationic ion-exchange resin,
Propylene weak acid cation exchange resin, metering system weak acid cation exchange resin, it is described in one or more mixture；Bag
Clothing material selection ethyl cellulose, cellulose acetate, shellac, polyvinyl acetate phthalic acid ester, butanedioic acid acetic acid hydroxypropyl
Cellulose, it is described in one or more mixture；Plasticizer selects dibutyl phthalate, phthalic acid diethyl
Ester, Macrogol 4000, dibutyl sebacate, triethyl citrate, it is described in one or more mixture.
In suspending system of the invention, described suspending agent selects Hydroxypropyl methylcellulose, methylcellulose, carboxymethyl cellulose
Plain sodium, glycerine, xanthans, tragacanth, PVP K90, microcrystalline cellulose, sodium alginate, Carbomer, it is described in
One or more mixture；Flavouring selects sucrose, mannitol, high fructose corn syrup, maltose, fructose, A Sipa
Smooth, essence, it is described in one or more mixture；PH conditioning agents select citric acid, sodium citrate, potassium citrate, mountain
Pears acid, lactic acid, malic acid, it is described in one or more mixture；Preservative selects methyl hydroxybenzoate, ethyl hydroxy benzoate, hydroxyl
Phenylpropyl alcohol ester, butyl hydroxybenzoate, benzoic acid, Sodium Benzoate, it is described in one or more mixture；Pigment from amaranth,
It is carmine, lure red, quinoline yellow, lemon yellow, sunset yellow, bright basket, indigo basket, it is described in one or more mixture.
The preparation method of sustained release mixed suspension preparation of the invention, comprises the following steps：
Step 1 takes appropriate ion exchange resin, 80~100 mesh is crossed after suitably being embathed with 15~50% ethanol waters wet
Sieve, drying；Take in ambroxol hydrochloride and dried resin addition purified water, water removal is placed in being done in 30 DEG C~70 DEG C baking ovens after question response
It is dry.
Step 2 takes coating material and plasticizer is leached in 80~90% appropriate ethanol waters, with this solution to step
The rapid 1 ambroxol resin for obtaining is coated：Ambroxol resin is placed in fluidized-bed coating machine, starts fluid bed, with made
Standby coating solution is to the ambroxol coated granule obtained by its top spray coating, collection.
Step 3 sequentially adds purified water, suspending agent, flavouring, PH conditioning agents, preservative, color in suitable container
Element, fully stirring, mixing, is subsequently adding ambroxol coated granule, stirs and evenly mixs, and is eventually adding purified water to full dose.
The present invention compared with prior art, solves the drawbacks of related sustained release preparation is present in the prior art, and it is by many
Tiny pastille is coated resin particle composition, adds suspending agent, flavouring, PH conditioning agents, preservative, pigment and purified water to be made
Sustained release suspension oral formulations, improve the biddability of patient's medication, solve children, old man and have the compliance of dysphagia patients
Property, due to adding flavouring, it is particularly suitable for children taking.Preparation of the invention drug release stabilization, to the excitant of intestines and stomach more
It is small, can be high 12 hours close to constant speed release medicine, bioavilability.
Specific embodiment
In order that those skilled in the art more fully understands technical scheme, with reference to embodiment to this hair
It is bright to be described in further detail.
Embodiment 1：
Prescription：
Preparation technology：
Step 1 takes the styrene cationic ion-exchange resin of recipe quantity, and 100 are crossed after suitably being embathed with 30% ethanol water
Mesh wet screening, drying；Take in ambroxol hydrochloride and dried resin addition purified water, water removal is placed in being done in 70 DEG C of baking ovens after question response
It is dry.
Step 2 takes ethyl cellulose and diethyl phthalate is leached in 85% appropriate ethanol water, uses this
The ambroxol resin that solution is obtained to step 1 is coated：Ambroxol resin is placed in fluidized-bed coating machine, starts fluidisation
Bed, with prepared coating solution to the ambroxol coated granule obtained by its top spray coating, collection.
Step 3 sequentially adds appropriate purified water, Hydroxypropyl methylcellulose, sucrose, glycerine, citric acid, oxybenzene in a reservoir
Ethyl ester, amaranth, essence, fully stirring, mixing, are subsequently adding ambroxol coated granule, stir and evenly mix, and are eventually adding purified water
To full dose, obtain final product.
Embodiment 2：
Prescription：
Preparation technology：
Step 1 takes the propylene weak acid cation exchange resin of recipe quantity, and 80 mesh are crossed after suitably being embathed with 25% ethanol water
Wet screening, drying；Take in ambroxol hydrochloride and dried resin addition purified water, water removal is placed in being dried in 60 DEG C of baking ovens after question response.
Step 2 takes cellulose acetate and dibutyl sebacate is leached in 80% appropriate ethanol water, uses this solution
The ambroxol resin obtained to step 1 is coated：Ambroxol resin is placed in fluidized-bed coating machine, starts fluid bed, used
Prepared coating solution is to the ambroxol coated granule obtained by its top spray coating, collection.
Step 3 sequentially add in a reservoir appropriate purified water, Hydroxypropyl methylcellulose, glycerine, sorbic acid, aspartame,
Methyl hydroxybenzoate, Nipasol, lemon yellow, essence, fully stirring, mixing, are subsequently adding ambroxol coated granule, stir and evenly mix,
Purified water to full dose is eventually adding, is obtained final product.
Embodiment 3：
Prescription：
Preparation technology：
Step 1 takes the styrene cationic ion-exchange resin and propylene weak acid cation exchange resin of recipe quantity, uses 50% ethanol
The aqueous solution crosses 80 mesh wet screenings, drying after suitably embathing；Take in ambroxol hydrochloride and dried resin addition purified water, removed water after question response
It is placed in being dried in 45 DEG C of baking ovens.
Step 2 insect-taking glue and triethyl citrate are leached in 87% appropriate ethanol water, with this solution to step
The 1 ambroxol resin for obtaining is coated：Ambroxol resin is placed in fluidized-bed coating machine, starts fluid bed, with prepared
Coating solution to its top spray be coated, collect obtained by ambroxol coated granule.
Step 3 sequentially adds appropriate purified water, tragacanth, high fructose corn syrup, malic acid, benzene first in a reservoir
Sour sodium, famille rose, stirring, fully mix, and are subsequently adding ambroxol coated granule, stir and evenly mix, and are eventually adding purified water to complete
Amount, obtains final product.
Embodiment 4：
Prescription：
Preparation technology：
Step 1 takes the metering system weak acid cation exchange resin of recipe quantity, mistake after suitably being embathed with 35% ethanol water
100 mesh wet screenings, drying；Take in ambroxol hydrochloride and dried resin addition purified water, water removal is placed in 70 DEG C of baking ovens after question response
Dry.
Step 2 takes polyvinyl acetate phthalic acid ester and dibutyl sebacate, triethyl citrate are leached in appropriate
In 90% ethanol water, the ambroxol resin obtained to step 1 with this solution is coated：Ambroxol resin is placed in fluidisation
In bed seed-coating machine, start fluid bed, with prepared coating solution to the ambroxol coated granule obtained by its top spray coating, collection.
Step 3 sequentially adds appropriate purified water, xanthans, sucrose, mannitol, potassium citrate, benzene first in a reservoir
Acid, ethyl hydroxy benzoate, sunset yellow, essence, fully stirring, mixing, are subsequently adding ambroxol coated granule, stir and evenly mix, and finally add
Enter purified water to full dose, obtain final product.
Embodiment 5：
Prescription：
Preparation technology：
Step 1 takes the styrene cationic ion-exchange resin of recipe quantity, and 80 mesh are crossed after suitably being embathed with 40% ethanol water
Wet screening, drying；Take in ambroxol hydrochloride and dried resin addition purified water, water removal is placed in being dried in 60 DEG C of baking ovens after question response.
Step 2 takes butanedioic acid acetic acid HPMC and Macrogol 4000 is leached in 80% appropriate ethanol water
In solution, the ambroxol resin obtained to step 1 with this solution is coated：Ambroxol resin is placed in fluidized-bed coating machine
In, start fluid bed, with prepared coating solution to the ambroxol coated granule obtained by its top spray coating, collection.
Step 3 sequentially add in a reservoir appropriate purified water, sodium carboxymethylcellulose, PVP K90,
Mannitol, maltose, sodium citrate, benzoic acid, the red, lemon yellow of temptation, essence, stirring, fully mixing are subsequently adding ambroxol
Coated granule, stirs and evenly mixs, and is eventually adding purified water to full dose, obtains final product.
Extracorporeal releasing test：
Subjects：Inventive samples and commercially available ambroxol hydrochloride oral liquid in above-described embodiment 1.
Content of the test：Release data of both contrasts under different sample times.
Testing conditions：According to ultraviolet-visible light photometry (two annex IVA of Chinese Pharmacopoeia version in 2015), in the ripple of 248nm
Strong point mensuration absorbance.
Dissolution medium：0.5M KCl 900ml.
Dissolution determination method：According to two annex release degree the first methods of determination method of Chinese Pharmacopoeia 2015 edition, using dissolution
The degree subtraction unit of determination method second, rotating speed is 75 turns per minute, samples 15ml (samplings at 1 hour, 4 hours and 12 hours respectively
Simultaneously not to supplementing dissolution medium in solution), filtration, precision is measured during subsequent filtrate 10ml puts 50ml measuring bottles, plus purified water is to carving
Degree, shakes up, and determines trap.Another 80 DEG C of drying under reduced pressure of learning from else's experience are appropriate to the ambroxol hydrochloride reference substance of constant weight, accurately weighed, plus
Water is made in every 1ml the solution containing about 75ug, is measured in the same method, and calculates the dissolution rate of each sample under different dissolution times.Knot
Fruit see the table below：
The preferred embodiment for the present invention is the foregoing described, so it is not limited to the present invention.Those skilled in the art couple
Embodiment disclosed herein can carry out the improvement without departing from scope and spirit.
Claims (10)
1. a kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm, it is characterised in that the preparation by ambroxol coated granule and
Suspending system is constituted, by weight percentage：Ambroxol coated granule is 0.5%~10%, and suspending system is 90%~99.5%；
The ambroxol coated granule includes ambroxol, ion exchange resin, coating material and plasticizer；The suspending system bag
Include suspending agent, flavouring, PH conditioning agents, preservative, pigment and purified water.
2. sustained release mixed suspension preparation according to claim 1, it is characterised in that ion exchange resin selects styrene cation
Exchanger resin, propylene weak acid cation exchange resin, metering system weak acid cation exchange resin, it is described in one or more
Mixture.
3. sustained release mixed suspension preparation according to claim 1, it is characterised in that coating material selects ethyl cellulose, acetic acid
Cellulose, shellac, polyvinyl acetate phthalic acid ester, butanedioic acid acetic acid HPMC, it is described in one or two with
On mixture.
4. sustained release mixed suspension preparation according to claim 1, it is characterised in that plasticizer from dibutyl phthalate,
Diethyl phthalate, Macrogol 4000, dibutyl sebacate, triethyl citrate, it is described in one or more
Mixture.
5. sustained release mixed suspension preparation according to claim 1, it is characterised in that suspending agent selects Hydroxypropyl methylcellulose, methyl
Cellulose, sodium carboxymethylcellulose, glycerine, xanthans, tragacanth, PVP K90, microcrystalline cellulose, marine alga
Sour sodium, Carbomer, it is described in one or more mixture.
6. sustained release mixed suspension preparation according to claim 1, it is characterised in that flavouring selects sucrose, mannitol, Gao Guoyu
Rice syrup, maltose, fructose, aspartame, essence, it is described in one or more mixture.
7. sustained release mixed suspension preparation according to claim 1, it is characterised in that PH conditioning agents from citric acid, sodium citrate,
Potassium citrate, sorbic acid, lactic acid, malic acid, it is described in one or more mixture.
8. sustained release mixed suspension preparation according to claim 1, it is characterised in that preservative from methyl hydroxybenzoate, ethyl hydroxy benzoate,
Nipasol, butyl hydroxybenzoate, benzoic acid, Sodium Benzoate, it is described in one or more mixture.
9. sustained release mixed suspension preparation according to claim 1, it is characterised in that pigment selects amaranth, famille rose, temptation
Red, quinoline yellow, lemon yellow, sunset yellow, bright basket, indigo basket, it is described in one or more mixture.
10. it is according to claim 1 sustained release mixed suspension preparation preparation method, it is characterised in that：
Step 1 takes appropriate ion exchange resin, 80~100 mesh wet screenings is crossed after suitably being embathed with 15~50% ethanol waters, is dried
It is dry；Take in ambroxol hydrochloride and dried resin addition purified water, water removal is placed in being dried in 30 DEG C~70 DEG C baking ovens after question response；
Step 2 takes coating material and plasticizer is leached in 80~90% appropriate ethanol waters, with this solution to step 1
The ambroxol resin for obtaining is coated：Ambroxol resin is placed in fluidized-bed coating machine, starts fluid bed, with prepared
Coating solution is to the ambroxol coated granule obtained by its top spray coating, collection；
Step 3 sequentially adds purified water, suspending agent, flavouring, PH conditioning agents, preservative, pigment in suitable container, stirs
Mix, fully mix, be subsequently adding ambroxol coated granule, stir and evenly mix, be eventually adding purified water to full dose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611242931.8A CN106727301A (en) | 2016-12-25 | 2016-12-25 | A kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611242931.8A CN106727301A (en) | 2016-12-25 | 2016-12-25 | A kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727301A true CN106727301A (en) | 2017-05-31 |
Family
ID=58923732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611242931.8A Pending CN106727301A (en) | 2016-12-25 | 2016-12-25 | A kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727301A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109771372A (en) * | 2019-03-26 | 2019-05-21 | 江苏四环生物制药有限公司 | A kind of dextromethorphan hydrobromide sustained-release suspension and preparation method thereof |
| CN114129514A (en) * | 2021-11-15 | 2022-03-04 | 华萃国际生物科技(广东)有限公司 | Suspension drop and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546008A (en) * | 2003-12-02 | 2004-11-17 | 沈阳药科大学 | Ambroxol hydrochloride liquid sustained release preparation and preparation method thereof |
| CN105663038A (en) * | 2016-02-03 | 2016-06-15 | 北京诺康达医药科技有限公司 | Liquid slow-release preparation and preparation method thereof |
-
2016
- 2016-12-25 CN CN201611242931.8A patent/CN106727301A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546008A (en) * | 2003-12-02 | 2004-11-17 | 沈阳药科大学 | Ambroxol hydrochloride liquid sustained release preparation and preparation method thereof |
| CN105663038A (en) * | 2016-02-03 | 2016-06-15 | 北京诺康达医药科技有限公司 | Liquid slow-release preparation and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘宏飞 等: "盐酸氨溴索药物树脂混悬剂的制备及物理稳定性的研究", 《中国新药杂志》 * |
| 曾环想 等: "右美沙芬树脂口服缓释混悬液的制备及其释药特性研究", 《中国新药杂志》 * |
| 许真玉 等: "离子交换树脂控释混悬剂的研究进展", 《沈阳药科大学学报》 * |
| 顾觉奋: "离子交换树脂药物载体在给药系统中的应用", 《离子交换与吸附》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109771372A (en) * | 2019-03-26 | 2019-05-21 | 江苏四环生物制药有限公司 | A kind of dextromethorphan hydrobromide sustained-release suspension and preparation method thereof |
| CN114129514A (en) * | 2021-11-15 | 2022-03-04 | 华萃国际生物科技(广东)有限公司 | Suspension drop and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014305430B2 (en) | Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof | |
| CN101836952A (en) | Ambroxol injection and preparation method thereof | |
| WO2006030297A1 (en) | Taste masked granules comprising clarithromycin, hydrocolloids and a coating | |
| CN106963777B (en) | Preparation method and application of baicalin-berberine compound | |
| CN106727301A (en) | A kind of sustained release mixed suspension preparation of breathing problem eliminating the phlegm and preparation method thereof | |
| CN102008667B (en) | Preparation method for traditional Chinese medicine composition with antibacterium and antiphlogosis efficacies | |
| CN103479583B (en) | Potassium sodium dehydroandroan drographolide succinate enteric dry suspension and preparation method thereof | |
| CN102908331A (en) | Duloxetine hydrochloride enteric capsules and preparation method thereof | |
| CN114272213A (en) | Florfenicol powder and preparation method thereof | |
| CN104922140B (en) | A kind of tylonolide composition and its application in treating or preventing fowl upper disease | |
| CN101869595A (en) | Preparation method and quality detection method of liquorice and gall oral liquid | |
| CN107362354A (en) | A kind of oral insulin nanometer formulation and preparation method thereof | |
| CN106727302A (en) | A kind of sustained release preparation for kobadrin and preparation method thereof | |
| CN106389562A (en) | Pudilan Xiaoyan granules, preparation method thereof, and product quality control method | |
| CN107019739A (en) | Blue oral liquid of a kind of cordate houttuynia a kind of reed mentioned in ancient books and preparation method thereof and product quality control method | |
| CN104069133B (en) | A kind of water solublity Lachnum melanin and the purposes as decorporation lead medicine thereof | |
| CN102579536A (en) | Enteric Panax Notoginseng total saponin preparation and preparation method thereof | |
| CN106361718B (en) | The colon target biology adhesion tablet of monosialotetrahexose ganglioside sodium | |
| CN113413402B (en) | Application of plum blossom extract in preparation of medicine for treating helicobacter pylori infection disease | |
| CN104721234A (en) | Periplaneta Americana extract product ion-activated in-situ gel and preparation method thereof | |
| CN102600210B (en) | A kind of compound DM Cough agent and preparation method thereof | |
| CN107056959A (en) | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation | |
| CN103301074B (en) | Diammonium glycyrrhizinate enteric-coated pellet as well as preparation method and preparation thereof | |
| WO2017157922A1 (en) | Prolonged release pharmaceutical composition comprising cysteamine or salt thereof | |
| CN106265684A (en) | The application of Lupenyl acetate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |